A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-18

Study Completion Date

2025-09-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to learn how belzutifan (MK-6482) affects the levels of metformin in a healthy person's body over time. Researchers will study levels of metformin in the blood and urine in healthy volunteers after taking metformin alone (Period 1) and metformin with belzutifan (Period 2).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants

NCT03796182

Healthy

COMPLETED PHASE1

Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

NCT01819272

Type 2 Diabetes Mellitus

COMPLETED PHASE2

A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants

NCT01719614

Healthy Participants

COMPLETED PHASE1

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

NCT00546728

Impaired Glucose Tolerance

COMPLETED PHASE4

Effect of BMS-986165 on the Blood Levels of Metformin

NCT04671953

Healthy Participants

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metformin

On Day 1 of Period 1, a single dose of metformin will be administered.

Group Type EXPERIMENTAL

Metformin

Intervention Type DRUG

Oral Tablet

Belzutifan with Metformin

In Period 2, belzutifan will be administered every day for 5 consecutive days with a single dose of metformin coadministered on Day 4.

Group Type EXPERIMENTAL

Metformin

Intervention Type DRUG

Oral Tablet

Belzutifan

Intervention Type DRUG

Oral Tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin

Oral Tablet

Intervention Type DRUG

Belzutifan

Oral Tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Metformin HCl MK-6482

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is a continuous non-smoker for at least 3 months prior to dosing
* Has body mass index (BMI) ≥ 18.0 and ≤ 42.0 kg/m2
* Is able to swallow multiple tablets

Exclusion Criteria

* Has a history of cancer (malignancy)
* Has a history of anemia within the last 5 years
* Has a known history or presence of metabolic acidosis, ketoacidosis, or lactic acidosis
* Has a hemoglobin level below the lower limit of normal
* Has a pulse oximetry reading less than 92% at rest
* Is known to be a cytochrome P450 (CYP2C19) poor metabolizer or likely poor metabolizer based on genotyping prior to the screening visit or is determined to be a CYP2C19 poor metabolizer

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes